HOME >> MEDICINE >> NEWS
Long-term outcomes for prostate cancer show IMRT Curative: 89 percent disease-free 8 years later

NEW YORK, September 27, 2006 -- Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate cancer patients treated with IMRT at Memorial Sloan-Kettering Cancer Center were classified into prognostic risk groups. After an average of eight years, 89 percent of the men in the favorable risk group were disease-free and none of the men in any group developed secondary cancers as a result of the radiation therapy. This report, published in the October 2006 issue of The Journal of Urology, is the first description of long-term outcomes for prostate cancer patients using IMRT.

"Our results suggest that IMRT should be the treatment of choice for delivering high-dose, external beam radiotherapy for patients with localized prostate cancer," said Dr. Michael J. Zelefsky, Chief of the Brachytherapy Service at Memorial Sloan-Kettering. "We were able to show long-term safety and long-term efficacy in a very diverse group of prostate cancer patients that we followed many for as long as ten years. Despite the fact that some patients had an aggressive form of their disease with high Gleason scores and PSA (prostate specific antigen) levels, the overwhelming majority of patients had good tumor control with neither recurrence of their original cancer nor development of second cancers, which one might have expected from the high doses of radiation," he added. Pre-treatment diagnostic evaluations were performed for all of the patients to better define their clinically localized prostate cancer. They were classified into prognostic risk groups as defined by the National Comprehensive Cancer Network guidelines (www.nccn.org). These are based on clinical characteristics including age, T stage, Gleason score, PSA level, and pre-treatm
'"/>

Contact: Joanne Nicholas
nicholaj@mskcc.org
212-639-3137
Memorial Sloan-Kettering Cancer Center
27-Sep-2006


Page: 1 2

Related medicine news :

1. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
2. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
3. Long-term aspirin use associated with reduced risk of dying in women
4. Long-term data on safety and effectiveness of antiobesity drugs needed
5. Long-term financial costs associated with prostate cancer treatment
6. Long-term effects of non-alcoholic fatty liver disease
7. Long-term abstinence may resolve many of the neurocognitive deficits associated with alcoholism
8. Long-term safety results released for breast cancer drugs
9. Long-term ibuprofen regimen after brain injury worsens cognition in animal study
10. Media availability: Long-term survival of heart attack patients with shock
11. Long-term estrogen therapy linked to breast cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2020)... ... 11, 2020 , ... Soterius, Inc., a global provider of ... a new, significantly larger business premises in Lawrenceville, NJ. The move supports the ... of digital technology platforms. , “As our customer base and offerings continue to ...
(Date:2/11/2020)... ... February 11, 2020 , ... Dental ... is pleased to announce a $5,000 grant to provide free dental care for ... generously donated to the Smiles for Everyone Foundation , which provides free ...
(Date:2/10/2020)... ... February 10, 2020 , ... A January 26 article on ... situations. The answer is that – not unlike the skin’s response to dangerous conditions ... serve as an alert to potential damage being done and warn the individual to ...
(Date:2/10/2020)... ... February 10, 2020 , ... ... president in the company’s healthcare division. In this role, Nikki will support Buxton’s ... the company’s continued healthcare product development. , “The healthcare industry is increasingly ...
(Date:2/10/2020)... Md. (PRWEB) , ... February 10, 2020 , ... ... the Public Health and Epidemiology Practice, has been elected president of the ... Group where she and her team develop and implement award-winning, research-driven Federal social ...
Breaking Medicine News(10 mins):
(Date:2/13/2020)... ... February 13, 2020 , ... Results of a new Freedom Debt Relief ... maintaining a generally positive outlook on the state of their personal finances as the ... better off today than a year ago, 43% said they feel the same financially, ...
(Date:2/13/2020)... ... 13, 2020 , ... Worldwide Business with kathy ireland® ... Founder and Leukemia Lymphoma Society's Woman of The Year Candidate Carmen Milagro to ... and founded in San Francisco, Borbón Skincare is a premium skincare brand with ...
(Date:2/11/2020)... ... February 11, 2020 , ... Terry Moore, a renowned business leader ... launch of Homeolux ™ and the company’s Beacon40 ™ product line. Singularly ... health and technology company that designs wellness products based on cutting-edge scientific research. With ...
Breaking Medicine Technology:
Cached News: